The conclusion that there are a huge number of potential targets for ASDs is all but unavoidable. Despite the

large number of target loci we identify and the small number of recurrent loci detected in this analysis, several of the events that we find supplement previous studies. For example, NRXN1 (encoding neurexin 1) is a well-established candidate gene underlying ASDs as well as schizophrenia ( Ching et al., 2010, Kim et al., 2008 and Pinto selleck et al., 2010); the 44 kb deletion in family 12119 extends the number of known ASD-causing variants in the 2p16.3 region. Similarly, homozygous mutations in ADSL lead to adenylosuccinate lyase deficiency (OMIM #103050) and autistic features ( Marie et al., 1999 and Stone et al., 1992); ADSL haploinsufficency (family 12224) may also lead to an ASD phenotype. More recently, maternally inherited deletions at the X-linked DDX53 locus (encoding a DEAD-box RNA helicase of unknown function)

have been linked to ASDs in males ( Pinto et al., 2010). The deletion of DDX53 in a male proband from family 12561 is the first known ASD-associated de novo mutation at this locus. The linkage of the X chromosomal NLGN3 locus (encoding neuroligin 3) to ASDs has been somewhat unclear, as this conclusion was based on a single maternally Ipatasertib inherited missense mutation that cosegregated with autistic diagnoses in two brothers from one family ( Jamain et al., 2003). The 33 kb deletion in NLGN3 (family 11689) discovered in this study provides the first independent confirmation for a role of NLGN3 mutations in the pathogenesis of ASDs. At the present time, target genes in most de novo events cannot be known with certainty.

First, mutations in any given candidate loci, even the recurrent ones, might be coincidental and unrelated to ASDs. Second, most events are large, disrupting more than one gene (and often dozens). Third, multiple genes within an event might act in concert. Fourth, attempts by biologists to discern the true functional subsets of genes in candidate loci cannot easily be subjected to rigorous statistical evaluation. For this reason, we have attempted to perform automated functional network analysis (-)-p-Bromotetramisole Oxalate in a companion paper (Gilman et al., 2011). That study concludes that among the diversity there is also evidence of functional convergence upon synaptogenesis, axon guidance, and neuron motility. Although the studies of Gilman et al. and others (Bill and Geschwind, 2009 and Pinto et al., 2010) argue for functional convergence, there is “evidence” to support almost any mechanism. Some potential targets encode proteins involved in neurotransmitter metabolism (ABAT in family 11551), synaptic proteins (NRXN1 and NLGN3, as mentioned above), and growth cones (BAIAP2 in family 11186).